lung cancer patients with air flow limitation scheduled for surgical treatment
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: The following conditions must all be met: (1) The participant is enrolled in the "RehaBoost" trial (IoT based perioperative telerehabilitation intervention for lung cancer patients with air flow limitation, a multicenter randomized phase II trial; jRCTs042230112) and has not withdrawn their consent, including consent for the secondary use of data. (2) Written consent has been obtained from the participant regarding participation in this ancillary study.
Exclusion criteria
Exclusion criteria: (1) Patients deemed unsuitable for this study by the principal investigator (2) Any other individuals deemed unsuitable by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of biomarkers for postoperative physical activity and intensity associated with the 6-minute walk test distance (change from preoperative levels at 3 months post-surgery) using AI | — |
Secondary
| Measure | Time frame |
|---|---|
| AI-driven identification of biomarkers for postoperative physical activity and intensity (6-minute walk test distance [change from preoperative to 6-month postoperative levels], changes in respiratory function, changes in PHR [resting heart rate, VO2max, etc.] obtained from Fitbit Inspire 3, changes in quality of life) AI-based exploration of biomarkers for postoperative complications (preoperative cardiopulmonary function, preoperative physical activity levels and intensity, surgical procedure, presence or absence of remote rehabilitation intervention, etc.) Association between surgical procedure and changes in skeletal muscle mass Association between surgical procedure and pre- and postoperative epigenome (DNA methylation age, etc.) Association between the epigenome (DNA methylation age, etc.) and postoperative complications, skeletal muscle mass, physical activity levels and intensity | — |
Contacts
Shizuoka Cancer Center